CD38 and melanoma: Collectively, our results suggest that targeting CD38 in the melanoma TME may be a beneficial approach to treat melanoma both as a neoadjuvant treatment, to reduce tumor growth before resection of primary tumor, as well as for inhibiting the occurrence of metastasis.